MedTrace Logo

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

NCT00356525 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2010-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to help answer:

* Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last
* Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer

Conditions

  • Lung Neoplasms

Interventions

DRUG

pemetrexed

500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

DRUG

gemcitabine

1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

DRUG

carboplatin

area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression

DRUG

Pemetrexed

500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-06-30
Completion
2009-04-30

Countries

  • United States
  • Brazil
  • India

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356525 on ClinicalTrials.gov